Peroxisome proliferator -activated receptor-delta (PPAR-␦ ) is overexpressed in human colon cancer, but its contribution to colonic tumorigenesis is controversial. We generated a mouse model in which PPAR-␦ was genetically disrupted in colonic epithelial cells by targeted deletion of exon 4. Elimination of colon-specific PPAR- 
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tional factor and inhibited tumorigenesis ( 9 , 10 ) . The alternative strategy that targeted exon 8 ( 8 , 11 ) , the last PPAR-␦ exon, is postulated to produce a hypomorphic PPAR-␦ protein that remains at least partly functional. This hypothesis is supported by the observation of high rates of embryonic mortality, subsequent to abnormal trophoblastic giant cell differentiation and abnormal placental development, when exon 4 but not exon 8 of PPAR-␦ was deleted ( 7 , 10 ) .
To further elucidate the role of PPAR-␦ in intestinal tumorigenesis, we generated mice with a tissue-specifi c disruption of exon 4 of the gene for PPAR-␦ in which deletion of PPAR-␦ expression was targeted to the intestine (Supplementary Methods and Materials, available online). The advantage of this approach was that it would avoid the deleterious effects of unrestricted exon 4 deletion on mouse embryonic development and associated embryonic lethality ( 7 , 10 ) . Briefl y, mice that were heterozygous for the gene for Crerecombinase directed expression by the intestine-specifi c villin promoter, and mice that were homozygous for a PPAR-␦ allele with exon 4 fl anked with loxP sites were mated to generate PPAR-␦ (+/ Ϫ ) and PPAR-␦ ( Ϫ / Ϫ ) mice in which tissue-specifi c expression of Cre-recombinase deleted PPAR-␦ exon 4 in the mouse intestine. The villinCre-recombinase mice (n = 3) were obtained from the National Cancer Institute Mouse Models Repository (Frederick, MD), and Peroxisome proliferator -activated receptordelta (PPAR-␦ ), a member of the ligandactivated PPAR nuclear receptor family, is overexpressed in human colon cancers ( 1 , 2 ) and in experimentally induced colon tumors in rodents ( 2 ) . However, the role of PPAR-␦ in colon tumorigenesis remains controversial. Studies in human colon cancer cell models have indicated that PPAR-␦ promotes the development of colon tumors. For example, xenografts of human HCT-116 colon cancer cells with a genetic deletion of PPAR-␦ exons 4 -6 form tumors more slowly than wild-type (WT) HCT-116 cells in immunodeficient mice ( 3 ) . Inhibition of PPAR-␦ by nonsteroidal antiinflammatory drugs suppresses survival of HCT-116, SW480, RKO, and DLD-1 human colon cancer cells in vitro ( 1 , 4 ) , and PPAR-␦ promotes survival of HCT-116 and LoVo colorectal cancer cells by inhibiting PPAR-␥ -mediated apoptosis ( 5 ) . In contrast, studies of PPAR-␦ in experimental mouse models of colonic tumorigenesis have yielded conflicting results.
Activation of PPAR-␦ using a synthetic ligand in Apc Min mice, a commonly used mouse model of intestinal tumorigenesis in which a mutation in the adenomatous polyposis coli ( Apc ) tumor suppressor gene markedly increases intestinal polyp formation, promotes intestinal tumorigenesis ( 6 ) . By contrast, germline deletion of PPAR-␦ exon 4 in Apc Min mice failed to reduce intestinal tumor incidence in one study ( 7 ) , but germline deletion of PPAR-␦ exon 8 in Apc Min mice increased intestinal tumor incidence in another ( 8 ) . More recently, deletion of exons 4 and part of exon 5 of PPAR-␦ was shown to inhibit intestinal tumorigenesis in Apc Min mice ( 9 ) . The confl icting results regarding the effect of PPAR-␦ knockout on intestinal tumorigenesis in Apc Min mice have been attributed to differences in the PPAR-␦ genetic disruption strategies ( 9 ) . The strategy that targeted exon 4, which encodes an essential portion of the PPAR-␦ DNAbinding domain, was predicted to disrupt PPAR-␦ function as a nuclear transcrip-the mice with the loxP -fl anked exon 4 of PPAR-␦ (n = 1) were a gift from Dr Ronald Evans (Salk Institute, La Jolla, CA). Both mouse strains were bred into a genetic background that was 95% or more FVB/N (FVB) because it is more effi cient than other genetic backgrounds with respect to azoxymethane (AOM)-induced colonic tumorigenesis ( 12 ) . Progeny mice (n = 4) were genotyped using polymerase chain reaction to amplify the PPAR-␦ (WT and with loxP -fl anked exon 4) and Cre-recombinase alleles from genomic DNA that was extracted from tail tissue (Supplementary Methods and Materials and Supplementary Figure 1 , available online). To characterize PPAR-␦ expression and function in the intestine, mice were killed by CO 2 asphyxiation and the entire intestinal tract was removed from each mouse, colons were dissected longitudinally and washed in phosphate-buffered saline, further sectioned, and digested with dispase and collagenase at 37°C for 15 minutes to release colon crypts (Supplementary Methods and Materials, available online). Total RNA was isolated from colonic crypts, heart, liver, and kidney specimens from 6-to 8-week-old WT mice, mice with Cre but without the loxP -fl anked (fl oxed) PPAR-␦ exon 4 (Cre), mice with the fl oxed PPAR-␦ exon 4 but not Cre (PPAR-␦ Flox), or mice with Cre that were heterozygous or homozygous for PPAR-␦ exon 4 deletion (PPAR-␦ (+/ Ϫ ) , PPAR-␦ ( Ϫ / Ϫ ) ) to measure relative levels of Cre-recombinase and PPAR-␦ mRNA by real-time reverse transcription -polymerase chain reaction (RT-PCR). Targeting of Cre expression to the intestine ( Figure 1, A ) abolished the expression of PPAR-␦ mRNA in the intestine but not other organs ( Figure 1, B ) .
In additional experiments, protein was extracted from the isolated colonic crypts of mice of WT, Cre, PPAR-␦ Flox, and PPAR-␦ ( Ϫ / Ϫ ) genotypes, and immunoblots confi rmed that PPAR-␦ expression was absent in PPAR-␦ ( Ϫ / Ϫ ) mice ( Figure 1, C ) . Also, colonic crypt cells were plated in collagen-coated wells and were immediately treated with the PPAR-␦ ligand GW0742 (1 µ M for 24 hours) or vehicle (dimethyl sulfoxide) before RNA extraction and real-time RT-PCR to measure expression of the gene for adipose differentiationrelated protein ( ADRP ), a known PPAR-␦ target ( 10 ) . The absence of PPAR-␦ mRNA and protein expression ( Figure 1 , B and C ) were associated with a statistically significant reduction in the baseline levels of ADRP expression ( P < .001) and with a total loss of PPAR-␦ agonist GW0742-stimulated ADRP expression in colonic epithelial cells ( Figure 1, D ) . Interestingly, compared with WT or Cre mice, PPAR-␦ Flox mice had similar PPAR-␦ mRNA levels but markedly lower PPAR-␦ protein expression and activity in the colon ( Figure 1 , C and D ). These fi ndings indicated that the loxP sequence insertion fl anking PPAR-␦ exon 4 likely reduced PPAR-␦ protein expression and activity through posttranscriptional mechanisms.
To test the effects of PPAR-␦ genetic disruption on colonic tumorigenesis, mice were injected intraperitoneally with the carcinogen AOM, a method that simulates human colorectal tumorigenesis better than genetic methods (eg, Apc Min mutation) or other chemical methods (eg, methylnitrosourea-induced tumorigenesis) ( 13 ) . At 6 -8 weeks of age, 10 -11 mice of each genotype (WT, Cre, PPAR-␦ Flox, PPAR-␦ (+/ Ϫ ) , and PPAR-␦ ( Ϫ / Ϫ ) ) were administered 250 µ L of isotonic saline containing 10 mg AOM per kg body weight once a week for 6 weeks or were given saline alone as a control (see Supplementary Methods and Materials for details, available online). In accordance with protocol, all mice were killed by CO 2 asphyxiation at 20 weeks after the last dose of AOM. Colorectal tumorigenesis was evaluated both by counting the number of colon tumors per mouse and by histological examination of representative tumors.
Targeted PPAR-␦ genetic disruption profoundly inhibited AOM-induced colonic tumorigenesis. In the various experimental groups (WT, Cre, PPAR-␦ Flox, PPAR-␦ (+/ Ϫ ) , and PPAR-␦ ( Ϫ / Ϫ ) ), AOM induced colonic adenocarcinomas that were histologically very similar to human colonic adenocarcinoma ( Figure 1 , E ). WT mice developed a mean of 6.6 tumors per mouse ( Table 1 ; Figure 1 , F and G ). However, mice that were heterozygous for the exon 4 deletion of PPAR-␦ (PPAR-␦ (+/ Ϫ ) ) developed, on average, only 3.0% as many tumors per mouse as WT control mice (mean = 0.2 tumors per PPAR-␦ (+/ Ϫ ) mouse, difference = 6.4, 95% confi dence interval [CI] = 4.8 to 7.9 tumors per mouse, P < .001), and mice that were homozygous for the exon 4 deletion developed only 1.5% as many tumors as WT control mice (mean = 0.1 tumors per PPAR-␦ ( Ϫ / Ϫ ) mouse, difference = 6.5, 95% CI = 4.9 to 8.0 tumors per mouse, P < .001) ( Table 1 ; Figure 1 , F and G ). In addition, colonic tumor formation was statistically signifi cantly inhibited for all tumor size categories in the PPAR-␦ (+/ Ϫ ) and PPAR-␦ ( Ϫ / Ϫ ) mice ( Table 1 ) . PPAR-␦ Flox mice, in which PPAR-␦ protein expression and function were reduced but not absent, developed 15% as many tumors as WT control mice (mean = 1.0 tumor per PPAR-␦ Flox mouse, difference [vs WT] = 5.6 tumors per mouse, 95% CI = 3.9 to 7.2 tumors per mouse, P < .001), but 5-fold more tumors than PPAR-␦ (+/ Ϫ ) mice (difference = 0.8 tumors, 95% CI = 0.04 to 1.56 tumors per mouse, P = .038) and 10-fold more tumors than PPAR-␦ ( Ϫ / Ϫ ) mice (difference = 0.9 tumors, 95% CI = 0.15 to 1.65 tumors per mouse, P = .028) ( Figure 1 , F and G and Table 1 ). These data clearly indicated that PPAR-␦ has a positive infl uence on susceptibility to colonic tumorigenesis. Furthermore, these data indicated that the extent of colonic tumorigenesis depended on the amount of remaining PPAR-␦ function.
Various molecular events have been implicated in the promotion of carcinogenesis by PPAR-␦ , including induction of COX-2 expression and prostaglandin E 2 (PGE 2 ) production ( 14 , 15 ), PGE 2 receptor subtype EP4 expression through phosphatidylinositol-3 kinase signaling ( 16 ) , activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) ( 17 ) , increased expression of vascular endothelial growth factor (VEGF) ( 9 , 18 , 19 ) , reduction of the proapoptotic cell death -inducing DFF45-like effector A and B levels and increase of antiapoptotic inhibitor of caspaseactivated deoxyribonuclease short and long forms ( ICAD-S and ICAD-L ) ( 20 ) , activation of the antiapoptotic Akt1 pathway ( 21 ) via 3-phosphoinositide -dependent kinase-1 (PDK1) and integrin-linked kinase activity ( 22 ) , increased NF-B activation and matrix metalloproteinase-9 secretion ( 22 ), suppression of PTEN expression ( 23 ) , and transcriptional activation of 14-3-3 ⑀ protein ( 24 ) . VEGF is increasingly being recognized to promote tumorigenesis via both angiogenic and nonangiogenic mechanisms ( 25 ) , and the effects of PPAR-␦ on VEGF expression during tumorigenesis are ). Values are means with 95% confi dence intervals of the means based on triplicate measurements from pooled samples from three mice (three repeated measurements showed similar results). The relative expression levels were calculated as the values relative to that of the calibrator sample (colon of Cre mice). Crerecombinase expression levels in colonic epithelial cells were statistically signifi cantly higher in Cre and PPAR-␦ ( Ϫ / Ϫ ) mice than other mice or other organs ( P < .001, two-way analysis of variance [ANOVA]). B ) PPAR-␦ mRNA expression levels, measured by quantitative real-time RT-PCR from the same RNA samples from the same groups of mice as in (A). Colonic epithelial cell PPAR-␦ expression levels were statistically signifi cantly lower in PPAR-␦ ( Ϫ / Ϫ ) mice than in other organs or mouse groups (eg, WT, PPAR-␦ Flox) ( P < .001, two-way ANOVA). Values are means and 95% confi dence intervals of triplicate measurements from pooled samples from three mice (three repeated measurements showed similar results). The relative expression levels were calculated as the values relative to that of the calibrator sample (colon of WT mice). C ) PPAR-␦ protein expression in dissected colonic epithelial cells from the indicated mice, as determined by immunoblots probed with a rabbit anti-mouse PPAR-␦ antibody. Blots were stripped and probed with a rabbit polyclonal anti-actin antibody as a control for loading and transfer. + = positive control (mouse PPAR-␦ expression vector-transfected cells). Three independent experiments were performed, and results were similar in each experiment. D ) Effects of PPAR-␦ genetic deletion on PPAR-␦ activity. Primary colonic epithelial cells were isolated from the indicated mice, and the cells were treated with either PPAR-␦ agonist (GW0742, +) or vehicle solution (control, -). controversial because of confl icting fi ndings in the literature. In vitro, the PPAR-␦ ligand GW501516 was reported to stimulate VEGF expression in bladder, breast, and colon cancer cell lines ( 9 , 18 , 19 ) , and PPAR-␦ was necessary for GW501516 to stimulate VEGF expression ( 9 ) . In vivo, GW501516 increased VEGF protein expression in intestinal adenomas of Apc Min mice ( 9 ) . However, others have reported that the PPAR-␦ agonists GW0742 and GW501516 failed to increase VEGF expression in cancer cell lines in vitro and that GW0742 failed to increase VEGF in colonic polyps of Apc Min mice ( 26 ) . We therefore also examined the effects of PPAR-␦ genetic disruption on VEGF expression in the AOM colonic tumorigenesis model. For these experiments, VEGF mRNA levels were measured by real-time RT-PCR from total RNA extracted from tumor vs normal colon tissue from mice of each genotype, as in previous experiments. VEGF relative expression levels were then calculated relative to levels in nonmalignant colon tissue from WT mice.
Mice in which PPAR-␦ was genetically disrupted exhibited a smaller increase in VEGF mRNA expression in tumors compared with WT or Cre control mice -the ratio of the VEGF mRNA levels in tumor vs nonmalignant colon cells in PPAR-␦ ( Ϫ / Ϫ ) mice was 37.5% of that in WT mice and 25% of that in Cre mice ( Figure 1, H ; Table 1 ). Relative to the calibrator sample (nonmalignant colon of WT mice), tumors of WT mice had 6.6-fold more VEGF mRNA, tumors of Cre mice had 7.8-fold more VEGF mRNA, but tumors of PPAR-␦ ( Ϫ / Ϫ ) mice had only 2.8-fold more VEGF mRNA ( Table 1 ) tumors: difference = 5.0-fold, 95% CI = 4.6 to 5.5-fold, P < .001). The PPAR-␦ Flox mice, which also had decreased PPAR-␦ protein expression and function, also had tumors containing somewhat less VEGF mRNA than tumors of WT mice or Cre control mice ( Table 1 ). Relative to nonmalignant colon of WT mice, tumors of PPAR-␦ Flox mice had 4.29-more VEGF mRNA (WT vs PPAR-␦ Flox tumors: difference = 2.3-fold, 95% CI = 1.8 to 2.8-fold, P < .001; Cre vs PPAR-␦ Flox tumors: difference = 3.5-fold, 95% CI = 3.0 to 4.1-fold, P < .001). Levels of VEGF mRNA in PPAR-␦ Flox tumors were higher than those in PPAR-␦ ( Ϫ / Ϫ ) tumors ( Table 1 ) (difference = 1.5-fold, 95% CI = 1.1 to 1.91-fold, P < .001), indicating that the extent of VEGF expression was inversely proportional to the degree of reduction in PPAR-␦ function. These fi ndings strongly suggest that PPAR-␦ expression in colon cancer cells promotes VEGF expression and thus challenge the previously proposed hypothesis that expression of PPAR-␦ in stromal cells, not tumor cells, promotes tumor angiogenesis ( 27 ) .
Our fi ndings demonstrate the effects of PPAR-␦ on colonic tumorigenesis in the fi rst mouse model with genetic disruption of PPAR-␦ targeted to colonic epithelial cells. Our targeted approach successfully abolished PPAR-␦ expression and activity in the intestine and had no effects on embryonic mouse development (data not shown), in contrast to what was observed in mouse models that used germline genetic disruption of PPAR-␦ exon 4 ( 7 , 10 ) . A previous study ( 9 ) that had used germline genetic disruption of PPAR-␦ exons 4 and 5 showed a threefold decrease in intestinal adenoma formation in Apc Min mice that were homozygous for the PPAR-␦ deletion compared with Apc Min mice with WT PPAR-␦ . The current study using intestine-specifi c deletion of PPAR-␦ and AOM-induced colonic carcinogenesis, which is a more representative model of human colorectal tumorigenesis than the one using Apc Min mice ( Apc Min mice usually develop intestinal adenomas, but the AOMinduced mice usually develop colonic adenocarcinomas), showed more profound effects. Tumor incidence in this study was 65-fold lower in PPAR-␦ ( Ϫ / Ϫ ) mice than in WT mice. , and PPAR-␦ ( Ϫ / Ϫ ) mice vs wild-type mice.
|| P = .69 for Cre and P < .001 for PPAR-␦ Flox, PPAR-␦
, and PPAR-␦ ( Ϫ / Ϫ ) mice vs wild-type mice. ¶ P = .09, P = .04, P < .001, and P < .001, respectively, for Cre, PPAR-␦ Flox, PPAR-␦
, and PPAR-␦ ( Ϫ / Ϫ ) mice vs wild-type mice.
In another study ( 8 ) , PPAR-␦ genetic disruption increased AOM-induced colonic tumorigenesis, in contrast to our current fi ndings. The different mouse genetic backgrounds used in the two studies, FVB in the current study vs C57BL/6 in the previous report, could have contributed to the contrasting results. However, we believe that the most plausible explanation for the confl icting results is that in our model, PPAR-␦ exon 4 deletion effectively abolished PPAR-␦ function in colonic epithelial cells, whereas in the previous study ( 10 ) , exon 8 was targeted, which might have inadequately inhibited PPAR-␦ function. Also, it has been postulated that PPAR-␦ , like other gene products ( 27 ) , could have a different role in stromal cells as opposed to epithelial cells during colonic tumorigenesis. Germline deletion of PPAR-␦ was used in the previous study ( 8 ) , whereas in our study, PPAR-␦ was selectively deleted from colonic epithelial cells. The current fi ndings are novel in fi nding that PPAR-␦ can act specifi cally in cancer cells to promote tumorigenesis and tumor angiogenesis.
This study has some potential limitations. We used a single type of genetic deletion in PPAR-␦ in a single mouse genetic background, and of course, carcinogenesis could be different in mice than in humans. In addition, we targeted deletion of PPAR-␦ to colonic epithelial cells, as opposed to the colon in general, which could be considered a limitation if carcinogenesis were to require the contribution of nonepithelial cells independently of cancer epithelial cells. The relative contribution of stromal cell -specifi c PPAR-␦ expression to tumorigenesis and tumor angiogenesis will require future studies that selectively genetically delete PPAR-␦ from tumor stromal cells in the colon.
Our study suggests that therapeutics that inhibit PPAR-␦ function might inhibit the growth of colon cancers. To date, with the exception of one recent report that characterized a selective PPAR-␦ antagonist in vitro ( 28 ) , the fi eld of PPAR-␦ therapeutic targeting has been limited to the development of PPAR-␦ agonists for treatment of diseases other than cancer ( 28 ) . Our current demonstration of the substantial involvement of PPAR-␦ in colonic tumorigenesis should stimulate future efforts to test PPAR-␦ inhibitors for the treatment and prevention of colon cancer and should serve to caution against clinical testing of PPAR-␦ agonists without a complete preclinical evaluation of their possible capacity to promote tumorigenesis.
